Your browser doesn't support javascript.
loading
Deep whole-genome analysis of 494 hepatocellular carcinomas.
Chen, Lei; Zhang, Chong; Xue, Ruidong; Liu, Mo; Bai, Jian; Bao, Jinxia; Wang, Yin; Jiang, Nanhai; Li, Zhixuan; Wang, Wenwen; Wang, Ruiru; Zheng, Bo; Yang, Airong; Hu, Ji; Liu, Ke; Shen, Siyun; Zhang, Yangqianwen; Bai, Mixue; Wang, Yan; Zhu, Yanjing; Yang, Shuai; Gao, Qiang; Gu, Jin; Gao, Dong; Wang, Xin Wei; Nakagawa, Hidewaki; Zhang, Ning; Wu, Lin; Rozen, Steven G; Bai, Fan; Wang, Hongyang.
Affiliation
  • Chen L; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China. chenlei@smmu.edu.cn.
  • Zhang C; Biomedical Pioneering Innovation Center (BIOPIC), Beijing Advanced Innovation Center for Genomics (ICG), School of Life Sciences, Peking University, Beijing, China.
  • Xue R; Peking University-Yunnan Baiyao International Medical Research Center, International Cancer Institute, Department of Medical Bioinformatics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Liu M; Translational Cancer Research Center, Peking University First Hospital, Beijing, China.
  • Bai J; Centre for Computational Biology and Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
  • Bao J; Berry Oncology Corporation, Beijing, China.
  • Wang Y; Model Animal Research Center, Medical School, Nanjing University, Nanjing, China.
  • Jiang N; Berry Oncology Corporation, Beijing, China.
  • Li Z; Centre for Computational Biology and Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
  • Wang W; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Wang R; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Zheng B; Berry Oncology Corporation, Beijing, China.
  • Yang A; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Hu J; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Liu K; Berry Oncology Corporation, Beijing, China.
  • Shen S; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Zhang Y; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Bai M; Berry Oncology Corporation, Beijing, China.
  • Wang Y; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Zhu Y; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Yang S; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Gao Q; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Gu J; Berry Oncology Corporation, Beijing, China.
  • Gao D; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Wang XW; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Nakagawa H; National Center for Liver Cancer/Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Zhang N; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Wu L; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Rozen SG; MOE Key Laboratory for Bioinformatics, Department of Automation, Tsinghua University, Beijing, China.
  • Bai F; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, CAS, Shanghai, China.
  • Wang H; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Nature ; 627(8004): 586-593, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38355797
ABSTRACT
Over half of hepatocellular carcinoma (HCC) cases diagnosed worldwide are in China1-3. However, whole-genome analysis of hepatitis B virus (HBV)-associated HCC in Chinese individuals is limited4-8, with current analyses of HCC mainly from non-HBV-enriched populations9,10. Here we initiated the Chinese Liver Cancer Atlas (CLCA) project and performed deep whole-genome sequencing (average depth, 120×) of 494 HCC tumours. We identified 6 coding and 28 non-coding previously undescribed driver candidates. Five previously undescribed mutational signatures were found, including aristolochic-acid-associated indel and doublet base signatures, and a single-base-substitution signature that we termed SBS_H8. Pentanucleotide context analysis and experimental validation confirmed that SBS_H8 was distinct to the aristolochic-acid-associated SBS22. Notably, HBV integrations could take the form of extrachromosomal circular DNA, resulting in elevated copy numbers and gene expression. Our high-depth data also enabled us to characterize subclonal clustered alterations, including chromothripsis, chromoplexy and kataegis, suggesting that these catastrophic events could also occur in late stages of hepatocarcinogenesis. Pathway analysis of all classes of alterations further linked non-coding mutations to dysregulation of liver metabolism. Finally, we performed in vitro and in vivo assays to show that fibrinogen alpha chain (FGA), determined as both a candidate coding and non-coding driver, regulates HCC progression and metastasis. Our CLCA study depicts a detailed genomic landscape and evolutionary history of HCC in Chinese individuals, providing important clinical implications.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Genome, Human / Carcinoma, Hepatocellular / High-Throughput Nucleotide Sequencing / Whole Genome Sequencing / Liver Neoplasms / Mutation Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Nature Year: 2024 Type: Article Affiliation country: China

Full text: 1 Database: MEDLINE Main subject: Genome, Human / Carcinoma, Hepatocellular / High-Throughput Nucleotide Sequencing / Whole Genome Sequencing / Liver Neoplasms / Mutation Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Nature Year: 2024 Type: Article Affiliation country: China